Gene-editing in immune cell lines can be challenging due to low targeting efficiency and difficulties in single cell derivation of suspension cells. Horizon has validated 10+ immune cell lines including THP-1, Jurkat and NALM-6 cells for gene-editing projects. CRISPR, rAAV and ZFN gene-editing technologies are available depending on project requirements.
Take advantage of the largest panel of pre-characterized immune cell lines available and benefit from Horizon’s exceptional knowhow and experience in completing over 2,000 gene-editing projects.
|Cell line||Species||Cell Type||Disease|
|THP-1||Human||Monocyte||Acute monocytic leukemia|
|MOLT-4||Human||T-lymphoblast||Acute lymphoblastic leukemia|
|NALM-6||Human||B-cell||Acute lymphoblastic leukemia|
|K-562||Human||Lymphoblast||Chronic myelogenous leukemia|
|Jurkat||Human||T-lymphocyte||Acute T-cell leukemia|
|J.RT3-T3.5||Human||T-lymphocyte||Acute T-cell leukemia|
|CCRF-CEM||Human||T-lymphoblast||Acute lymphoblastic leukemia|
|A20||Mouse||B-lymphocyte||Reticulum cell sarcoma|
|Case Study I: Heterozygous CRISPR Knockout in Jurkat Cells|
Positive clone with heterozygous knockout was identified by PCR and Sanger sequencing. An 11 bp deletion introducing a premature stop codon at position 51 exists in one allele.
|Case Study II: CRISPR-Mediated Gene Disruption in THP-1 Cells|
Following transfection of THP-1 cells with CRISPR targeting reagents directed against two genes, CRISPR mediated disruption of each gene was identified (indicated by *) by Surveyor assay.